GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

Novo Nordisk plans to resubmit an application to have Wegovy listed with the Pharmaceutical Benefits Advisory Committee, this year. Pharmaceutical companies argued there were economic benefits to ...

An "exciting" new study has found that Semaglutide, the active ingredient of Wegovy and Ozempic ... of evidence that the drugs may have other benefits. Importantly, the study found that ...

Dr Craig Koniver, a family physician in Charleston, South Carolina, said he currently has 200 patients using the same method ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

The first clinical trial of its kind found the weekly jab semaglutide, also known as Ozempic and Wegovy, cuts the amount ... evidence that the drug may have benefits beyond weight loss or ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Big pharma’s pushing for PBS funding, and it’s kickstarting a shift to healthier snacks, smaller portions, and more ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

The House Republicans’ budget blueprint, blessed by Speaker Mike Johnson, has long been stalled in the chamber. On Tuesday, Arrington called for a Thursday committee meeting to resolve vast ...